DNA synthesis inhibitors: Fluoroquinolones

27,473views

DNA synthesis inhibitors: Fluoroquinolones

Block 2

Block 2

Pentose phosphate pathway
Diabetes mellitus
Disorders of carbohydrate metabolism: Pathology review
Amino acid metabolism
Disorders of amino acid metabolism: Pathology review
Dyslipidemias: Pathology review
Drug misuse, intoxication and withdrawal: Alcohol: Pathology review
Diabetes mellitus (Type 2): Clinical sciences
Fatty acid synthesis
Wernicke-Korsakoff syndrome
Alcohol-induced hepatitis: Clinical sciences
Diabetes mellitus: Clinical
Diabetes mellitus (Type 1): Clinical sciences
Fetal alcohol syndrome
Diabetes mellitus: Pathology review
Alcohol use disorder
Alcohol-associated liver disease
Enterococcus
Staphylococcus epidermidis
Mycobacterium tuberculosis (Tuberculosis)
Neisseria gonorrhoeae
Corynebacterium diphtheriae (Diphtheria)
Water-soluble vitamin deficiency and toxicity: B1-B7: Pathology review
Water-soluble vitamin deficiency and toxicity: B9, B12 and vitamin C: Pathology review
Vitamin D
Klebsiella pneumoniae
Vitamin B12 deficiency
Folate (Vitamin B9) deficiency
Streptococcus viridans
Clostridium perfringens
Chlamydia trachomatis
Staphylococcus saprophyticus
Staphylococcus aureus
Mycobacterium leprae
Clostridium botulinum (Botulism)
Bacillus anthracis (Anthrax)
Actinomyces israelii
Clostridium tetani (Tetanus)
Streptococcus agalactiae (Group B Strep)
Bacillus cereus (Food poisoning)
Listeria monocytogenes
Pseudomonas aeruginosa
Nocardia
Haemophilus influenzae
Neisseria meningitidis
Treponema pallidum (Syphilis)
Human papillomavirus
Herpes simplex virus
Neuraminidase inhibitors
Human herpesvirus 6 (Roseola)
Borrelia burgdorferi (Lyme disease)
Adenovirus
Yersinia pestis (Plague)
Rhinovirus
Rubella virus
Influenza virus
Mumps virus
Measles virus
Human herpesvirus 8 (Kaposi sarcoma)
Herpesvirus medications
Plasmodium species (Malaria)
Coxiella burnetii (Q fever)
Ehrlichia and Anaplasma
Bartonella henselae (Cat-scratch disease and Bacillary angiomatosis)
Rickettsia rickettsii (Rocky Mountain spotted fever) and other Rickettsia species
Anthelmintic medications
Antimalarials
Trypanosoma cruzi (Chagas disease)
Francisella tularensis (Tularemia)
Candida
Anti-mite and louse medications
Miscellaneous antifungal medications
Azoles
Cytokines
Type I hypersensitivity
Type II hypersensitivity
Type III hypersensitivity
Type IV hypersensitivity
Hyper IgM syndrome
Leukocyte adhesion deficiency
Chronic granulomatous disease
X-linked agammaglobulinemia
Wound healing
Complement deficiency
Inflammation
Pulmonary corticosteroids and mast cell inhibitors
Selective immunoglobulin A deficiency
Necrosis and apoptosis
Ischemia
Wiskott-Aldrich syndrome
Immunodeficiencies: Clinical
Non-corticosteroid immunosuppressants and immunotherapies
Intrinsic hemolytic normocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Blood groups and transfusions
Macrocytic anemia: Pathology review
Cytomegalovirus infection after transplant (NORD)
Glucocorticoids
Blood products and transfusion: Clinical
Acute intermittent porphyria
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Aplastic anemia
Sideroblastic anemia
Microcytic anemia: Pathology review
Erythropoietin
Post-transplant lymphoproliferative disorders (NORD)
Platelet disorders: Pathology review
Thrombotic thrombocytopenic purpura
Neonatal jaundice: Clinical
Jaundice: Clinical
Mixed platelet and coagulation disorders: Pathology review
Von Willebrand disease
Immune thrombocytopenia
Hemolytic-uremic syndrome
Extrinsic hemolytic normocytic anemia: Pathology review
Jaundice
Iron deficiency anemia
Anemia: Clinical
Graft-versus-host disease
Iron deficiency anemia: Clinical sciences
Autoimmune hemolytic anemia
Severe chronic neutropenia (NORD)
Anemia of chronic disease: Year of the Zebra
Jaundice: Pathology review
Blood transfusion reactions and transplant rejection: Pathology review
Anemia of chronic disease
Non-hemolytic normocytic anemia: Pathology review
Antimetabolites: Sulfonamides and trimethoprim
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Fluoroquinolones
Protein synthesis inhibitors: Aminoglycosides
Nucleotide metabolism
Adenosine deaminase deficiency
Purine and pyrimidine synthesis and metabolism disorders: Pathology review
Gout
Gout and pseudogout: Pathology review
Lesch-Nyhan syndrome
Gout: Clinical sciences
Oncogenes and tumor suppressor genes
Anti-tumor antibiotics
Blood histology
DNA synthesis inhibitors: Metronidazole
Deep vein thrombosis
Disseminated intravascular coagulation
Factor V Leiden
Protein C deficiency
Protein S deficiency
Miscellaneous cell wall synthesis inhibitors
Miscellaneous protein synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Antithrombin III deficiency
Heparin-induced thrombocytopenia
Antiphospholipid syndrome
Hemophilia
Hemophilia: Year of the Zebra
Protease inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Hepatitis medications
HIV and AIDS: Pathology review
Thrombosis syndromes (hypercoagulability): Pathology review
Mechanisms of antibiotic resistance
Coagulation disorders: Pathology review
Integrase and entry inhibitors
Leukemias: Pathology review
Myeloproliferative disorders: Pathology review
Lymphomas: Pathology review
Chronic leukemia
Acute leukemia
Non-Hodgkin lymphoma
Polycythemia vera (NORD)
Myelodysplastic syndromes
Hodgkin lymphoma
Essential thrombocythemia (NORD)
Waldenstrom macroglobulinemia
Multiple myeloma: Clinical sciences
Mastocytosis (NORD)
Plasma cell disorders: Pathology review
Plasma cell disorders: Clinical
Spleen histology
Myelofibrosis (NORD)
Lymphoma: Clinical
Varicella zoster virus
Coxsackievirus
Congenital TORCH infections: Pathology review
Streptococcus pyogenes (Group A Strep)
Lyme disease: Clinical sciences
Cortisol
Hematopoietic medications
Parvovirus B19
HIV (AIDS)
Zika virus

Transcript

Watch video only

Content Reviewers

Our bodies consist of eukaryotic cells, while bacterias consist of prokaryotic cells.

So, in order to treat bacterial infections we can develop antimicrobials that only target prokaryotic cells while leaving our cells mostly unharmed.

One of these targets is bacterial DNA, and we call these medications DNA inhibitors or nucleic acid inhibitors.

There are plenty of processes and enzymes involved that we can target and the quinolones and fluoroquinolones inhibit an enzyme called DNA topoisomerase.

So there are many different types of topoisomerases but we’ll be looking at topoisomerase II, also called DNA gyrase, and topoisomerase IV.

Both types of topoisomerases cause double strand breaks in DNA, but at different points during mitosis.

Topoisomerase II plays a role in condensing the chromosomes by making a double strand break in the DNA so that it can be more tightly wound, causing a supercoil.

When enough supercoils are induced, the DNA condenses.

Topoisomerase IV plays a role later on, after the chromosome has been replicated, where it causes a double strand break in the DNA so the new DNA strand can be disentangled from the original.

Now, quinolones are created to target bacterial topoisomerases, but it was soon discovered that by adding a fluorine molecule to the quinolones, they become more effective.

So these newer medications, called fluoroquinolones, replaced the older quinolones in most clinical settings.

Common fluoroquinolones include ciprofloxacin, ofloxacin, balofloxacin, levofloxacin, gemifloxacin, and moxifloxacin.

One way to tell a fluoroquinolone apart from other antimicrobials is that they all have the suffix “-floxacin.”

These medications can be taken peroral or via IV, but ciprofloxacin and ofloxacin are also available in otic formulations, while moxifloxacin is also available in ophthalmic solutions.

Now fluoroquinolones are broad spectrum bactericidal antibiotics and ciprofloxacin in particular is widely used.

They are very effective against gram negative bacterias like Enterobacteriaceae, Haemophilus, Legionella, Neisseria, Moraxella, and even Pseudomonas species.

They are also effective against certain mycobacteria and can be used for the treatment of tuberculosis.

However, more and more bacteria are becoming resistant to ciprofloxacin, either through mutations in the genes that code of topoisomerases, or through efflux pumps that pump the medication out.

Another downside is that the older fluoroquinolones are less effective against Gram positive bacteria, but the newer ones, like levofloxacin, gemifloxacin, and moxifloxacin, have improved effectiveness against Gram positive cocci, especially Streptococcus pneumoniae, so they are called respiratory fluoroquinolones since they are often used to treat hospital acquired pneumonia.

The trade off is that they are less effective against pseudomonas than ciprofloxacin.

Most fluoroquinolones are not effective against MRSA.

As a general rule, fluoroquinolones should not be taken perorally together with mineral supplements like iron, zinc, or calcium pills.

They’ll bind to each other, a process called chelation, preventing their absorption from the gut.

They are metabolized in the liver by a family of enzymes called cytochrome p450, but they are also inhibitors of this enzyme.

For side effects, fluoroquinolones can cause tendonitis especially in the achilles tendon, where they can cause it to rupture.

Due to this, they should not be used by active athletes and the elderly.